{
  "item1": "BD global medical technology company engaged development, manufacture sale broad range medical supplies, devices, laboratory equipment diagnostic products used healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry general public. provide customer solutions focused improving medication management patient safety; supporting infection prevention practices; equipping surgical interventional procedures; improving drug delivery; aiding anesthesiology care; enhancing diagnosis infectious diseases cancers; advancing cellular research applications. September 30, 2025, BD’s operations consisted three worldwide business segments: BD Medical, BD Life Sciences BD Interventional. further discussed Note 8 consolidated financial statements contained Item 8.",
  "item7": "Management’s Discussion Analysis Financial Condition Results Operations following commentary should read conjunction consolidated financial statements accompanying notes presented report. Within tables presented throughout discussion, certain columns may not add due use rounded numbers disclosure purposes. Percentages earnings per share amounts presented calculated underlying amounts. References years throughout discussion relate fiscal years, which end September 30.",
  "item2": "Item 2. Management’s Discussion Analysis Financial Condition Results Operations following commentary should read conjunction condensed consolidated financial statements accompanying notes presented report. Within tables presented throughout discussion, certain columns may not add due use rounded numbers disclosure purposes. Percentages earnings per share amounts presented calculated underlying amounts."
}